You searched for "regenerative"
Théa Pharmaceuticals are excited to be attending RCOphth Congress 2023 with two innovative new products.
22 May 2023
|
Research & Development, Awards, Conferences & Anniversaries
This year Théa will also have two stands – one right by the registration desk which will be focused on product sampling and a larger stand inside the main exhibition hall which will showcase the wider product range.
Understanding optical lab processes at 100% Optical
Boosting understanding amongst the entire practice team about what happens in the optical lens manufacturing process was a keynote lecture which drew a packed audience to the OSA stand at 100% Optical.
Efficacy and safety of novel PF brimonidine / timolol fixed-combination ophthalmic solution for OAG
4 August 2021
| Su Young
|
EYE - Glaucoma
|
Open-angle glaucoma, brimonidine/timolol fixed combination, intraocular pressure, normal-tension glaucoma, preservative-free
This study is a multicentre, randomised, open-label, parallel-group clinical trial to evaluate the efficacy and safety of a newly developed preservative-free (PF) brimonidine / timolol fixed-combination (BTFC) ophthalmic solutions as compared with preservative-containing (PC) BTFC ophthalmic solution in adult patients...
Understanding amniotic membrane grafts
Safa Elhassan gives a brief review of amniotic membrane grafts and their application in theatre and clinic-based settings. Amniotic membrane (AM) transplant has been an established adjuvant treatment for many corneal, conjunctival and scleral disorders in ophthalmic clinical practice with...Effective management of dry eye and ocular surface disease
4 August 2021
| Rod McNeil
|
EYE - General
Experts recommend a consistent approach to diagnosis, therapeutic targeting by disease subtype and escalation of therapy when tear substitutes are not sufficient. Experts call for a consistent, unified approach to diagnosis of dry eye disease (DED), with a new simple...
Outcome of secondary intraocular lens implantation-conventional 23- vs. modified 27-gauge vitrectomy port anchor fixation
This retrospective case study series evaluated the outcome of a secondary intraocular lens (IOL) implantation technique of a Carlevale IOL (Soleko IOL Division, Italy) with either a conventional 23- or a modified 27-gauge (-g) vitrectomy port used as anchor fixation....
Scleral fixation using Gore-Tex suture of a subluxated PCIOL
This was a retrospective single-centre study of patients who underwent lasso in-the-bag scleral fixation of a subluxated posterior chamber (PC) intraocular lens (IOL) using the snare technique with Gore-Tex suture from 2019 to 2021. Functional outcome was analysed by clinical...Can OCT predict Alzheimer’s disease?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Can OCT predict Alzheimer’s disease? In 1986 Hinton et al. demonstrated evidence of optic nerve degeneration...Eye disease patients have more opportunity than ever to take part in NHS research studies
1 November 2018
|
EYE - General
A new report highlights how 76% of UK hospitals now offer patients the opportunity to take part in studies of eye disease to improve research and innovation. ‘Ophthalmology research in the UK’s National Health Service: the structure and performance of...
Effect of preservative free fluoroquinolones on human corneal epithelial cells in vitro
Fluoroquinolones, including second generation (ofloxacin and ciprofloxacin), third generation (levofloxacin and tosufloxacin) and fourth generation (gatifloxacin and moxifloxacin), are a group of bactericidal agents used to treat multiple ocular infections. The third and fourth generation fluoroquinolones have enhanced Gram-positive activity...Broadening of treatment options for potentially blinding retinal conditions
2 August 2022
| Rod McNeil
|
EYE - General
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...
Update on emerging therapies for age-related macular degeneration
4 December 2023
| Rod McNeil
|
EYE - Vitreo-Retinal
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...
